Facts and figures
Placed initially on 4 November 2005 under the former company Biotec Pharmacon, ArcticZymes Technologies ASA is listed on the Oslo Stock Exchange. Being a global leader in development and commercialization of enzymes, we are working continuously on innovative, novel solutions and technologies. Our success stories is not only reflected in our current business figures but also the latest developments on the stock market. Take a look for yourself!
Reports and Finances
Get an insight into our current business developments with our quarterly reports.
Learn more
Shareholder Info
Take a look at the current stock market price and our 20 largest shareholders.
Learn more
Financial Calendar
More financial information
| Date | Presentation |
|---|---|
| 30 Jan 2020 | Presentation of the fourth quarter report 2019 and the preliminary annual accounts 2019 |
| 21 Apr 2020 | Annual report 2019 |
| 23 Apr 2020 | Presentation of the first quarter 2020 |
| 14 May 2020 | Annual General Meeting |
| 19 Aug 2020 | Presentation of the second quarter 2020 |
| 22 Oct 2020 | Presentation of the third quarter 2020 |
Recent stock exchange announcements
ArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate
July 2, 2020Biotec Pharmacon ASA rebrands as ArcticZymes Technologies ASA
June 22, 2020ArcticZymes granted NOK 1.6 million funding from Innovation Norway for enzyme development project.
June 22, 2020ArcticZymes granted NOK 1.65 million funding from Innovation Norway for a SAN-HQ upscaling project
May 20, 2020Mandatory Notifications of Trade
Notifications of disclosure of large shareholdings past 12 months